| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 40 | 2025 | 1131 | 1.890 |
Why?
|
| Heart Defects, Congenital | 3 | 2019 | 92 | 1.750 |
Why?
|
| Pregnancy Outcome | 7 | 2024 | 128 | 1.720 |
Why?
|
| Pregnancy Rate | 6 | 2024 | 45 | 1.650 |
Why?
|
| Insemination, Artificial | 5 | 2024 | 23 | 1.650 |
Why?
|
| Diabetes, Gestational | 3 | 2022 | 63 | 1.530 |
Why?
|
| Environmental Exposure | 5 | 2018 | 47 | 1.510 |
Why?
|
| Female | 68 | 2025 | 14463 | 1.370 |
Why?
|
| Live Birth | 6 | 2024 | 39 | 1.310 |
Why?
|
| Infertility | 7 | 2024 | 35 | 1.220 |
Why?
|
| Benzene | 2 | 2018 | 11 | 1.180 |
Why?
|
| Congenital Abnormalities | 3 | 2018 | 16 | 1.170 |
Why?
|
| Air Pollution | 2 | 2018 | 13 | 1.150 |
Why?
|
| Humans | 73 | 2025 | 26828 | 1.040 |
Why?
|
| Adult | 45 | 2025 | 7383 | 1.010 |
Why?
|
| Environmental Pollutants | 3 | 2017 | 32 | 0.990 |
Why?
|
| Retrospective Studies | 14 | 2025 | 2433 | 0.870 |
Why?
|
| Labor, Induced | 2 | 2020 | 19 | 0.850 |
Why?
|
| Oklahoma | 11 | 2024 | 973 | 0.840 |
Why?
|
| Case-Control Studies | 13 | 2022 | 700 | 0.830 |
Why?
|
| Parabens | 1 | 2022 | 5 | 0.820 |
Why?
|
| Young Adult | 22 | 2025 | 2581 | 0.800 |
Why?
|
| Caffeine | 4 | 2018 | 38 | 0.770 |
Why?
|
| Infant, Newborn | 11 | 2022 | 843 | 0.760 |
Why?
|
| Semen | 1 | 2021 | 27 | 0.750 |
Why?
|
| Arsenicals | 1 | 2021 | 5 | 0.740 |
Why?
|
| Arsenic | 1 | 2021 | 19 | 0.740 |
Why?
|
| Milk, Human | 2 | 2021 | 82 | 0.710 |
Why?
|
| Smoking | 5 | 2015 | 465 | 0.700 |
Why?
|
| Urinary Catheterization | 1 | 2020 | 15 | 0.700 |
Why?
|
| Cervical Ripening | 1 | 2020 | 6 | 0.690 |
Why?
|
| Oxytocics | 1 | 2020 | 5 | 0.690 |
Why?
|
| Adolescent | 23 | 2021 | 2957 | 0.690 |
Why?
|
| Catheters | 1 | 2020 | 23 | 0.680 |
Why?
|
| Dinoprostone | 1 | 2020 | 41 | 0.680 |
Why?
|
| Indians, North American | 7 | 2022 | 511 | 0.660 |
Why?
|
| Child | 11 | 2020 | 2147 | 0.640 |
Why?
|
| Infant | 7 | 2021 | 957 | 0.640 |
Why?
|
| Water Pollution | 1 | 2018 | 7 | 0.640 |
Why?
|
| Natural Gas | 1 | 2018 | 6 | 0.640 |
Why?
|
| Ovulation Induction | 4 | 2024 | 33 | 0.630 |
Why?
|
| Pregnancy Complications | 5 | 2025 | 105 | 0.620 |
Why?
|
| Cleft Palate | 1 | 2018 | 12 | 0.610 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 19 | 0.610 |
Why?
|
| Breast Feeding | 2 | 2021 | 87 | 0.600 |
Why?
|
| Infant Formula | 1 | 2017 | 18 | 0.590 |
Why?
|
| Pelvic Floor Disorders | 4 | 2021 | 21 | 0.580 |
Why?
|
| Alcohol Drinking | 4 | 2018 | 162 | 0.560 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 36 | 0.560 |
Why?
|
| Cohort Studies | 8 | 2021 | 858 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 32 | 0.550 |
Why?
|
| Infant, Premature | 1 | 2017 | 133 | 0.540 |
Why?
|
| Pelvic Floor | 5 | 2017 | 35 | 0.530 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 4 | 0.530 |
Why?
|
| Nitrogen Dioxide | 1 | 2016 | 3 | 0.530 |
Why?
|
| Leukemia | 1 | 2016 | 22 | 0.530 |
Why?
|
| Air Pollutants | 1 | 2016 | 14 | 0.520 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 137 | 0.520 |
Why?
|
| Health Promotion | 1 | 2017 | 169 | 0.520 |
Why?
|
| Ovarian Reserve | 1 | 2015 | 9 | 0.510 |
Why?
|
| Premenopause | 1 | 2015 | 20 | 0.510 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2020 | 17 | 0.490 |
Why?
|
| Life Style | 1 | 2015 | 83 | 0.490 |
Why?
|
| Male | 23 | 2024 | 12870 | 0.480 |
Why?
|
| Ovarian Follicle | 1 | 2015 | 84 | 0.480 |
Why?
|
| Puberty, Delayed | 2 | 2014 | 4 | 0.480 |
Why?
|
| Adolescent Development | 2 | 2014 | 8 | 0.480 |
Why?
|
| Asian Americans | 2 | 2018 | 40 | 0.470 |
Why?
|
| Breast Neoplasms | 7 | 2017 | 442 | 0.460 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2018 | 96 | 0.460 |
Why?
|
| Logistic Models | 6 | 2018 | 397 | 0.450 |
Why?
|
| Phthalic Acids | 2 | 2015 | 6 | 0.450 |
Why?
|
| Obesity | 4 | 2025 | 650 | 0.430 |
Why?
|
| Platelet Count | 3 | 2018 | 112 | 0.430 |
Why?
|
| Reproduction | 3 | 2018 | 63 | 0.410 |
Why?
|
| Progesterone | 2 | 2024 | 128 | 0.410 |
Why?
|
| Estrogens | 2 | 2003 | 56 | 0.400 |
Why?
|
| Neoplasms | 2 | 2023 | 755 | 0.400 |
Why?
|
| Cesarean Section | 3 | 2021 | 55 | 0.380 |
Why?
|
| Delivery, Obstetric | 4 | 2021 | 38 | 0.380 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2022 | 37 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 2 | 2022 | 53 | 0.360 |
Why?
|
| Fertilization in Vitro | 3 | 2021 | 24 | 0.350 |
Why?
|
| Endometrium | 2 | 2020 | 38 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 30 | 0.350 |
Why?
|
| Child, Preschool | 4 | 2017 | 1091 | 0.350 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 11 | 0.340 |
Why?
|
| Breast | 4 | 2012 | 51 | 0.330 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 910 | 0.330 |
Why?
|
| Middle Aged | 19 | 2024 | 6818 | 0.320 |
Why?
|
| Body Mass Index | 3 | 2025 | 386 | 0.320 |
Why?
|
| Odds Ratio | 4 | 2017 | 230 | 0.320 |
Why?
|
| Maternal Age | 1 | 2009 | 25 | 0.320 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2021 | 63 | 0.320 |
Why?
|
| Prospective Studies | 6 | 2024 | 1217 | 0.310 |
Why?
|
| Phenols | 2 | 2022 | 22 | 0.310 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2025 | 36 | 0.310 |
Why?
|
| African Americans | 3 | 2019 | 350 | 0.300 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 78 | 0.300 |
Why?
|
| Estrogens, Conjugated (USP) | 3 | 2017 | 14 | 0.300 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2017 | 42 | 0.290 |
Why?
|
| Muscle Strength | 3 | 2017 | 214 | 0.260 |
Why?
|
| Pilot Projects | 4 | 2022 | 390 | 0.250 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2015 | 19 | 0.250 |
Why?
|
| Pregnancy Trimester, First | 1 | 2025 | 14 | 0.240 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 133 | 0.240 |
Why?
|
| Azithromycin | 2 | 2022 | 10 | 0.240 |
Why?
|
| Biomarkers | 4 | 2022 | 733 | 0.240 |
Why?
|
| Vitamin D | 2 | 2018 | 44 | 0.240 |
Why?
|
| Eating | 2 | 2018 | 66 | 0.240 |
Why?
|
| Vasectomy | 1 | 2024 | 10 | 0.230 |
Why?
|
| Parity | 3 | 2021 | 48 | 0.230 |
Why?
|
| United States | 9 | 2022 | 2033 | 0.220 |
Why?
|
| Risk Factors | 9 | 2018 | 2011 | 0.210 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 18 | 0.210 |
Why?
|
| Phenol | 1 | 2022 | 7 | 0.210 |
Why?
|
| Birth Weight | 1 | 2003 | 63 | 0.200 |
Why?
|
| Age Factors | 5 | 2017 | 716 | 0.200 |
Why?
|
| Puerperal Infection | 1 | 2022 | 4 | 0.200 |
Why?
|
| Motivation | 1 | 2024 | 207 | 0.200 |
Why?
|
| Pregnant Women | 1 | 2022 | 23 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2015 | 300 | 0.200 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 6 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2022 | 90 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 90 | 0.200 |
Why?
|
| Population Surveillance | 2 | 2019 | 85 | 0.190 |
Why?
|
| Calcium, Dietary | 2 | 2012 | 11 | 0.190 |
Why?
|
| Hematoma | 1 | 2021 | 26 | 0.190 |
Why?
|
| Puerperal Disorders | 1 | 2021 | 14 | 0.190 |
Why?
|
| Time Factors | 2 | 2020 | 1562 | 0.190 |
Why?
|
| Cacodylic Acid | 1 | 2021 | 5 | 0.190 |
Why?
|
| Methylation | 1 | 2021 | 21 | 0.190 |
Why?
|
| Preoperative Care | 1 | 2021 | 76 | 0.180 |
Why?
|
| Sex Characteristics | 1 | 2021 | 162 | 0.180 |
Why?
|
| Appendicitis | 1 | 2000 | 14 | 0.180 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 77 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 128 | 0.170 |
Why?
|
| Administration, Intravaginal | 1 | 2020 | 12 | 0.170 |
Why?
|
| Oxytocin | 1 | 2020 | 5 | 0.170 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 38 | 0.170 |
Why?
|
| Pain Management | 1 | 2020 | 52 | 0.170 |
Why?
|
| Thrombocytopenia | 2 | 2018 | 113 | 0.170 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 59 | 0.170 |
Why?
|
| Acute Disease | 2 | 2016 | 153 | 0.170 |
Why?
|
| Obstetric Labor Complications | 2 | 2017 | 18 | 0.170 |
Why?
|
| Infertility, Female | 1 | 2020 | 42 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 189 | 0.170 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 102 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 59 | 0.160 |
Why?
|
| Mammography | 3 | 2010 | 77 | 0.160 |
Why?
|
| Emigrants and Immigrants | 2 | 2010 | 18 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2020 | 228 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 78 | 0.160 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 8 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2018 | 209 | 0.160 |
Why?
|
| Endosonography | 2 | 2015 | 36 | 0.150 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 456 | 0.150 |
Why?
|
| Gastroschisis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Breast Milk Expression | 1 | 2017 | 2 | 0.150 |
Why?
|
| Placenta | 1 | 2018 | 74 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 27 | 0.150 |
Why?
|
| Embryo Transfer | 2 | 2014 | 13 | 0.150 |
Why?
|
| Aged | 10 | 2019 | 5167 | 0.150 |
Why?
|
| Breast Density | 1 | 2017 | 10 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 5 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 464 | 0.140 |
Why?
|
| Postmenopause | 4 | 2017 | 83 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2020 | 2264 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 121 | 0.140 |
Why?
|
| Prevalence | 4 | 2021 | 472 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 213 | 0.140 |
Why?
|
| Smokers | 1 | 2017 | 124 | 0.130 |
Why?
|
| Infertility, Male | 1 | 1996 | 23 | 0.130 |
Why?
|
| Motor Vehicles | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 77 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 2015 | 22 | 0.130 |
Why?
|
| Palpation | 1 | 2015 | 7 | 0.130 |
Why?
|
| Linear Models | 3 | 2015 | 201 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 747 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2015 | 16 | 0.120 |
Why?
|
| Gestational Age | 3 | 2025 | 140 | 0.120 |
Why?
|
| Acupuncture Therapy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2017 | 194 | 0.110 |
Why?
|
| Enterocytes | 1 | 2013 | 14 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 33 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 242 | 0.110 |
Why?
|
| Creatinine | 2 | 2015 | 57 | 0.110 |
Why?
|
| Rectum | 1 | 2013 | 50 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 980 | 0.110 |
Why?
|
| Tobacco Use | 1 | 2014 | 83 | 0.110 |
Why?
|
| ROC Curve | 3 | 2014 | 139 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2013 | 6 | 0.110 |
Why?
|
| Labor Presentation | 1 | 2012 | 3 | 0.110 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2012 | 5 | 0.110 |
Why?
|
| Air Pollutants, Occupational | 1 | 2013 | 11 | 0.110 |
Why?
|
| Wisconsin | 2 | 2010 | 8 | 0.100 |
Why?
|
| Laos | 2 | 2009 | 6 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 186 | 0.100 |
Why?
|
| Self Report | 3 | 2020 | 116 | 0.100 |
Why?
|
| Cholecalciferol | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2013 | 77 | 0.100 |
Why?
|
| Clomiphene | 2 | 2021 | 11 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 578 | 0.090 |
Why?
|
| Fertility Agents, Female | 2 | 2021 | 15 | 0.090 |
Why?
|
| Meningococcal Infections | 1 | 2010 | 2 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 8 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 21 | 0.090 |
Why?
|
| Abortion, Spontaneous | 1 | 2010 | 15 | 0.090 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 10 | 0.090 |
Why?
|
| Fetal Death | 1 | 2010 | 21 | 0.090 |
Why?
|
| Demography | 1 | 2010 | 91 | 0.090 |
Why?
|
| Obstetric Labor, Premature | 1 | 2010 | 15 | 0.090 |
Why?
|
| Fetal Growth Retardation | 1 | 2010 | 30 | 0.090 |
Why?
|
| Vaccination | 2 | 2022 | 167 | 0.090 |
Why?
|
| Fertility | 1 | 2010 | 58 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2010 | 150 | 0.090 |
Why?
|
| Fishes | 1 | 2010 | 31 | 0.080 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2009 | 2 | 0.080 |
Why?
|
| Food Contamination | 1 | 2010 | 22 | 0.080 |
Why?
|
| Cerclage, Cervical | 1 | 2009 | 3 | 0.080 |
Why?
|
| Streptococcus agalactiae | 1 | 2009 | 11 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2009 | 44 | 0.080 |
Why?
|
| Cotinine | 1 | 2010 | 45 | 0.080 |
Why?
|
| Water Pollutants, Chemical | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cervix Uteri | 1 | 2009 | 63 | 0.080 |
Why?
|
| Diethylhexyl Phthalate | 1 | 2009 | 6 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 1927 | 0.080 |
Why?
|
| Education | 1 | 2009 | 33 | 0.080 |
Why?
|
| Health Care Surveys | 2 | 2019 | 67 | 0.080 |
Why?
|
| Kidney | 1 | 2010 | 275 | 0.080 |
Why?
|
| Seasons | 1 | 2009 | 83 | 0.080 |
Why?
|
| Spermatozoa | 2 | 2020 | 29 | 0.080 |
Why?
|
| Reproductive History | 1 | 2008 | 8 | 0.080 |
Why?
|
| Cultural Characteristics | 1 | 2008 | 27 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 60 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2018 | 38 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 496 | 0.070 |
Why?
|
| Cardiovascular System | 2 | 2018 | 39 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 508 | 0.070 |
Why?
|
| Family Characteristics | 2 | 2020 | 46 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 918 | 0.060 |
Why?
|
| Follicular Phase | 1 | 2024 | 8 | 0.060 |
Why?
|
| Birth Rate | 1 | 2024 | 11 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 759 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 2024 | 16 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2017 | 13 | 0.060 |
Why?
|
| Prenatal Care | 2 | 2017 | 40 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 12 | 0.050 |
Why?
|
| Texas | 2 | 2014 | 133 | 0.050 |
Why?
|
| Physical Examination | 2 | 2014 | 47 | 0.050 |
Why?
|
| Endometritis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Controlled Before-After Studies | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cefazolin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Human Genome Project | 1 | 2001 | 3 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2000 | 18 | 0.050 |
Why?
|
| Gonadotropins | 1 | 2020 | 22 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2000 | 15 | 0.050 |
Why?
|
| Genome, Human | 1 | 2001 | 67 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 83 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 203 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2000 | 48 | 0.040 |
Why?
|
| Insemination | 1 | 2020 | 6 | 0.040 |
Why?
|
| Sperm Count | 1 | 2020 | 13 | 0.040 |
Why?
|
| Urology | 1 | 2020 | 26 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 104 | 0.040 |
Why?
|
| Gynecology | 1 | 2020 | 55 | 0.040 |
Why?
|
| Phenotype | 2 | 2018 | 665 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2001 | 364 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2000 | 351 | 0.040 |
Why?
|
| Health Services | 1 | 2019 | 12 | 0.040 |
Why?
|
| Chorionic Villi | 1 | 2018 | 7 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 15 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 14 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 28 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 57 | 0.040 |
Why?
|
| Capillaries | 1 | 2018 | 32 | 0.040 |
Why?
|
| Women's Health | 2 | 2012 | 58 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 43 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2018 | 37 | 0.040 |
Why?
|
| Hyperandrogenism | 1 | 2018 | 11 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2018 | 74 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 198 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 116 | 0.040 |
Why?
|
| Calcium | 1 | 2018 | 231 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2018 | 116 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2017 | 4 | 0.040 |
Why?
|
| Gravidity | 1 | 2017 | 6 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2017 | 63 | 0.040 |
Why?
|
| Child Health | 1 | 2017 | 15 | 0.040 |
Why?
|
| Postnatal Care | 1 | 2017 | 16 | 0.040 |
Why?
|
| Oligospermia | 1 | 1996 | 1 | 0.030 |
Why?
|
| Y Chromosome | 1 | 1996 | 3 | 0.030 |
Why?
|
| Labor Stage, Second | 1 | 2016 | 4 | 0.030 |
Why?
|
| Oocytes | 1 | 1996 | 24 | 0.030 |
Why?
|
| Perineum | 1 | 2016 | 14 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 158 | 0.030 |
Why?
|
| Behavior | 1 | 2016 | 14 | 0.030 |
Why?
|
| Fetal Development | 1 | 2016 | 21 | 0.030 |
Why?
|
| Plants | 1 | 2016 | 64 | 0.030 |
Why?
|
| Fetus | 1 | 2016 | 77 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 472 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 107 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 94 | 0.030 |
Why?
|
| Diet | 1 | 2016 | 223 | 0.030 |
Why?
|
| Proctoscopy | 1 | 2013 | 1 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 2013 | 17 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 587 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 39 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 400 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 399 | 0.030 |
Why?
|
| Mass Screening | 1 | 2013 | 141 | 0.020 |
Why?
|
| Neisseria meningitidis | 1 | 2010 | 3 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 133 | 0.020 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 1 | 0.020 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 2 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2010 | 59 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2010 | 11 | 0.020 |
Why?
|
| Mercury | 1 | 2010 | 12 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 298 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2012 | 213 | 0.020 |
Why?
|
| Laparotomy | 1 | 2009 | 29 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 78 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 34 | 0.020 |
Why?
|
| Thailand | 1 | 2008 | 11 | 0.020 |
Why?
|
| Contraception | 1 | 2008 | 21 | 0.020 |
Why?
|
| Incidence | 1 | 2009 | 545 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 154 | 0.020 |
Why?
|
| Research Design | 1 | 2005 | 174 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 9961 | 0.010 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2001 | 4 | 0.010 |
Why?
|
| Retroelements | 1 | 2001 | 2 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2001 | 3 | 0.010 |
Why?
|
| DNA, Intergenic | 1 | 2001 | 4 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 8 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2001 | 5 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2001 | 17 | 0.010 |
Why?
|
| Genes | 1 | 2001 | 35 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2001 | 14 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2001 | 31 | 0.010 |
Why?
|
| CpG Islands | 1 | 2001 | 23 | 0.010 |
Why?
|
| Exons | 1 | 2001 | 41 | 0.010 |
Why?
|
| Introns | 1 | 2001 | 41 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 130 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 186 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2001 | 80 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2001 | 250 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2001 | 229 | 0.010 |
Why?
|
| Computational Biology | 1 | 2001 | 150 | 0.010 |
Why?
|
| Proteins | 1 | 2001 | 244 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2001 | 537 | 0.010 |
Why?
|
| Algorithms | 1 | 2001 | 419 | 0.010 |
Why?
|